Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025

Core Insights - Akero Therapeutics, Inc. is set to present findings from its clinical studies on efruxifermin (EFX) at the 76th Annual AASLD The Liver Meeting® 2025, focusing on its efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH) [1][2][3] Presentation Details - Two oral presentations will be made on November 9, 2025, highlighting the improvements in fibrosis regression and portal hypertension markers in patients with compensated cirrhosis due to MASH [2] - A poster presentation on November 10, 2025, will discuss AI-powered histology analysis revealing changes in liver microarchitecture in patients with pre-cirrhotic MASH [3] Company Overview - Akero Therapeutics is a clinical-stage company focused on developing treatments for serious metabolic diseases, particularly MASH, with efruxifermin as its lead product candidate [1][3] - The company is currently conducting three Phase 3 clinical studies under the SYNCHRONY program, building on results from two Phase 2b trials [3]